NCT00781872View on ClinicalTrials.gov

Mesenchymal Stem Cells for the Treatment of MS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Injection of autologous bone marrow derived mesenchymal stem cells

60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT00781872 - Mesenchymal Stem Cells for the Treatment of MS | Biotech Hunter | Biotech Hunter